Rapport Therapeutics, a clinical-stage biotech aiming to develop precision medicines for neurological disorders, launched Tuesday with $100 million in Series A financing.
https://www.pharmalive.com/wp-content/uploads/2023/02/BioSpacebraintablet2-27-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-03-07 09:47:532023-03-07 09:47:53J&J-backed Rapport Therapeutics snags $100M for precision approach to neurological diseases